Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines.

Overexpression of a 170kD membrane glycoprotein, P-glycoprotein (Pgp), which acts as an energy dependent efflux pump for cytotoxic drugs is believed to be one of the factors that is responsible for clinical drug resistance. Recent studies suggest that Pgp is also responsible for the intracellular transport of cholesterol from the plasma membrane to the endoplasmic reticulum. Leukemic cells from patients with acute myelogenous leukemia have an elevated uptake of low density lipoprotein (LDL) when compared with white blood cells from healthy individuals. Since elevated LDL receptor expression and multidrug resistance are both common events in leukemic cells, we investigated LDL receptor expression in sensitive and drug resistant human leukemic cell lines. We found a 2- to 10-fold higher uptake of LDL in five out of five drug resistant K562 cell lines. All three drug resistant HL60 cell lines studied also had higher uptake than the parental cells. The LDL receptor expression in vincristine resistant Pgp positive K562 cells was less sensitive to downregulation by sterols than in parental cells. There was no selective effect of the Pgp inhibitor PSC-833 or other Pgp modulators on LDL receptor activity in Pgp positive cells. Since also resistant Pgp, multidrug resistance protein 1, and breast cancer resistance protein negative cells exhibited an elevated LDL receptor activity, we conclude that overexpression of these proteins is not the mechanism behind the elevated LDL uptake in the drug resistant leukemic cell lines. The findings are of interest for the concept of using lipoproteins as carriers of cytotoxic drugs in cancer treatment.

[1]  J. Endicott,et al.  The biochemistry of P-glycoprotein-mediated multidrug resistance. , 1989, Annual review of biochemistry.

[2]  O. Larsson,et al.  Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo. , 1992, Cancer research.

[3]  E. Wang,et al.  Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. , 2000, Biochemical and biophysical research communications.

[4]  B. Tran,et al.  Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells , 1997, Cancer Chemotherapy and Pharmacology.

[5]  G. Juliusson,et al.  Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy- 3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells , 1994 .

[6]  E. Wattel,et al.  Expression of the multidrug resistance‐associated protein in myelodysplastic syndromes , 2000, British journal of haematology.

[7]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[8]  D. Hipfner,et al.  Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. , 1994, Cancer research.

[9]  M. Brown,et al.  Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. , 1974, The Journal of biological chemistry.

[10]  S. Vitols,et al.  Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. , 1997, Journal of lipid research.

[11]  M. Brown,et al.  Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. , 1983, Methods in enzymology.

[12]  Y. Chen,et al.  Human prostate cancer cells lack feedback regulation of low‐density lipoprotein receptor and its regulator, SREBP2 , 2001, International journal of cancer.

[13]  H. Li,et al.  Role of Multidrug Resistance P-glycoproteins in Cholesterol Biosynthesis (*) , 1996, The Journal of Biological Chemistry.

[14]  J. Pallarés‐Trujillo,et al.  Role of cell cholesterol in modulating vincristine uptake and resistance , 1993, International journal of cancer.

[15]  M. Müller,et al.  A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. , 1996, British Journal of Cancer.

[16]  M. A. Lasunción,et al.  Combination of an enzymatic method and HPLC for the quantitation of cholesterol in cultured cells. , 1992, Journal of lipid research.

[17]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[18]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[19]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[20]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[21]  M. Brown,et al.  Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. , 1978, Blood.

[22]  E. Simpson,et al.  Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. , 1981, American journal of obstetrics and gynecology.

[23]  H. Luthman,et al.  Quantitative determination of mdrl gene expression in leukaemic cells from patients with acute leukaemia , 2007 .

[24]  G. Gahrton,et al.  Significance of the low-density lipoprotein (LDL) receptor pathway for the in vitro accumulation of AD-32 incorporated into LDL in normal and leukemic white blood cells. , 1984, Cancer treatment reports.

[25]  J J Albers,et al.  Platelet-derived growth factor stimulates activity of low density lipoprotein receptors. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[26]  O. Larsson,et al.  Expression of the low-density lipoprotein receptor, HMG-CoA reductase, and multidrug resistance (Mdr1) genes in colorectal carcinomas. , 1996, Biochemical pharmacology.

[27]  S. Vitols,et al.  Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia , 1995, Medical oncology.

[28]  K. Einarsson,et al.  Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Sachs,et al.  Microviscosity in the surface membrane lipid layer of intact normal lymphocyte leukemic cells , 1974, FEBS letters.

[30]  X. Pan,et al.  Overexpression of a 40-kDa protein in human multidrug resistant cells. , 1997, Biochemical and biophysical research communications.

[31]  J. Avigan,et al.  Effect of cell density on binding and uptake of low density lipoprotein by human fibroblasts , 1979, The Journal of cell biology.

[32]  R. Levy,et al.  The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. , 1972, The Journal of clinical investigation.

[33]  P. Lipsky,et al.  Non-sterol regulation of low density lipoprotein receptor gene expression in T cells. , 1994, Journal of lipid research.

[34]  A. Mazzoni,et al.  Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells. , 1993, Oncology research.

[35]  Pramod M. Lad,et al.  Regulation of low-density lipoprotein receptors and assessment of their functional role in Burkitt's lymphoma cells. , 1995, Biochimica et biophysica acta.

[36]  M. Ikeguchi,et al.  Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. , 1993, Endocrinology.

[37]  A. Stopeck,et al.  Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. , 1993, Journal of Biological Chemistry.